Search

Your search keyword '"Imatinib resistant"' showing total 8 results
Start Over Descriptor "Imatinib resistant" Journal leukemia
8 results on '"Imatinib resistant"'

1. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

Author

Thoralf Lange, Thomas Ernst, Andreas Hochhaus, Richard A. Engh, Kimmo Porkka, Jacqueline Maier, Ingvild Mikkola, and Franz Gruber

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Dasatinib, Antineoplastic Agents, Drug resistance, Biology, Pharmacology, Imatinib resistant, Piperazines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, neoplasms, Hematology, medicine.disease, Thiazoles, Leukemia, Pyrimidines, Imatinib mesylate, Nilotinib, Drug Resistance, Neoplasm, Benzamides, Imatinib Mesylate, medicine.drug
Abstract

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

Published
2011

2. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

Author

Amy Harlow, Christopher A. Eide, Michael Heinrich, Michael W. Deininger, Anupriya Agarwal, Brian J. Druker, Christopher L. Corless, Michael J. Mauro, and Amie S. Corbin

Subjects
Cancer Research, business.industry, Myeloid leukemia, Hematology, Drug resistance, medicine.disease, Imatinib resistant, Proto-Oncogene Proteins p21(ras), Myelogenous, Leukemia, Imatinib mesylate, Oncology, Cancer research, medicine, business, Kras mutation
Published
2008

3. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

Author

S. Mousset, Wolf-K. Hofmann, Christoph Walz, Nicholas C.P. Cross, T. Klippstein, Andreas Hochhaus, Georgia Metzgeroth, Martina Teichmann, Helen J. Martin, Andreas Reiter, and Philipp Erben

Subjects
Adult, Male, Niacinamide, Sorafenib, Cancer Research, Receptor, Platelet-Derived Growth Factor alpha, Adolescent, Pyridines, Antineoplastic Agents, Drug resistance, urologic and male genital diseases, medicine.disease_cause, Imatinib resistant, Piperazines, hemic and lymphatic diseases, Hypereosinophilic Syndrome, medicine, Humans, neoplasms, Aged, mRNA Cleavage and Polyadenylation Factors, Chronic eosinophilic leukemia, Mutation, business.industry, Phenylurea Compounds, Benzenesulfonates, Hematology, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, digestive system diseases, Fip1l1 pdgfra, Pyrimidines, Imatinib mesylate, Oncology, Nilotinib, Drug Resistance, Neoplasm, Benzamides, Chronic Disease, Immunology, Imatinib Mesylate, Cancer research, business, medicine.drug
Abstract

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

Published
2011

4. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells

Author

Tomasz Skorski, Sylwia Flis, and Margaret Nieborowska-Skorska

Subjects
Cancer Research, Proto-Oncogene Proteins c-akt, Fusion Proteins, bcr-abl, Antineoplastic Agents, Biology, Imatinib resistant, Piperazines, Article, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, CD135, Humans, Progenitor cell, Protein kinase B, Protein Kinase Inhibitors, 030304 developmental biology, chemistry.chemical_classification, 0303 health sciences, Reactive oxygen species, Myeloid leukemia, Hematology, Virology, 3. Good health, Imatinib mesylate, Pyrimidines, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Benzamides, Cancer research, Imatinib Mesylate, Neoplastic Stem Cells, Reactive Oxygen Species
Abstract

AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells

Published
2014

5. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells

Author

Cassuto Jp, Maeva Dufies, Sophie Raynaud, Patrick Auberger, and Alexandre Puissant

Subjects
Cancer Research, Antineoplastic Agents, Tumor cells, Drug resistance, Biology, Imatinib resistant, Piperazines, Cathepsin B, Myelogenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Tumor Cells, Cultured, medicine, Humans, Neoplasm, RNA, Small Interfering, Hematology, Protein-Tyrosine Kinases, medicine.disease, Virology, Leukemia, Pyrimidines, Imatinib mesylate, Oncology, Drug Resistance, Neoplasm, Benzamides, Imatinib Mesylate, Lysosomes, Oligopeptides, Chronic myelogenous leukemia
Published
2010

6. BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

Author

Laurence Legros, Sophie Raynaud, Cassuto Jp, Jean-Pierre Magaud, Sandrine Hayette, Marie-Cécile Michallet, F. E. Nicolini, and Kaddour Chabane

Subjects
Cancer Research, business.industry, Hematology, Pharmacology, Imatinib resistant, chemistry.chemical_compound, Oncology, chemistry, hemic and lymphatic diseases, Homoharringtonine, Omacetaxine mepesuccinate, Medicine, business, neoplasms
Abstract

BCR-ABL T315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

Published
2007

7. Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

Author

E Rad-Quesnel, Aline Renneville, Claude Preudhomme, Selim Corm, Nathalie Grardel, and Bruno Quesnel

Subjects
Cancer Research, ABL, business.industry, breakpoint cluster region, Hematology, medicine.disease, Imatinib resistant, Transplantation, Dasatinib, Acute megakaryoblastic leukemia, Oncology, hemic and lymphatic diseases, medicine, Cancer research, Stem cell, business, neoplasms, medicine.drug, K562 cells
Abstract

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

Published
2007

8. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML

Author

Jean-Luc Laï, Claude Preudhomme, Franck-Emmanuel Nicolini, Thierry Facon, Ibrahim Yakoub-Agha, Selim Corm, Catherine Roche-Lestienne, Valeria Biggio, and Nathalie Philippe

Subjects
Hybrid gene, Cancer Research, medicine.medical_specialty, Hematology, Point mutation, Imatinib, Biology, Philadelphia chromosome, medicine.disease, Imatinib resistant, BCR-ABL protein, chemistry.chemical_compound, Oncology, RUNX1, chemistry, Internal medicine, medicine, Cancer research, medicine.drug
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results